Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: Salience processing and fear inhibition processes

Psychoneuroendocrinology

Volumn 40, Issue 1, 2014, Pages 242-256

  Koch, Saskia B J ^a   Van Zuiden, Mirjam ^a   Nawijn, Laura ^a   Frijling, Jessie L ^a   Veltman, Dick J ^b   Olff, Miranda ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Arq Psychotrauma Expert Group   (Netherlands)

Author keywords

Fear inhibition; Intranasal oxytocin; Medication enhanced psychotherapy; PTSD; Salience processing

Indexed keywords

OXYTOCIN;

AMYGDALOID NUCLEUS; ANXIETY; AUTONOMIC NERVOUS SYSTEM FUNCTION; BRAIN STEM; DRUG MECHANISM; FEAR; FUNCTIONAL ANATOMY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SOCIAL BEHAVIOR; TREATMENT RESPONSE; VENTROMEDIAL PREFRONTAL CORTEX;

FEAR INHIBITION; INTRANASAL OXYTOCIN; MEDICATION-ENHANCED PSYCHOTHERAPY; PTSD; SALIENCE PROCESSING;

ADAPTATION, PSYCHOLOGICAL; ADMINISTRATION, INTRANASAL; ANIMALS; COMBINED MODALITY THERAPY; FEAR; HUMANS; MENTAL PROCESSES; OXYTOCIN; PSYCHOTHERAPY; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84893371207     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2013.11.018     Document Type: Review

References (112)

1. Acheson D., Feifel D., de Wilde S., McKinney R., Lohr J., Risbrough V. The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology 2013, 229:199-208.
2. American Psychiatric Association DSM-V, Diagnostic and Statistical Manual of Mental Disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
3. Anagnostou E., Soorya L., Chaplin W., Bartz J., Halpern D., Wasserman S., Wang T., Pepa L., Tanel N., Kushki A., Hollander E. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Molecular Autism 2012, 3:16.
4. Andari E., Duhamel J.-R., Zalla T., Herbrecht E., Leboyer M., Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:4389-4394.
5. Bartz J.A., Simeon D., Hamilton H., Kim S., Crystal S., Braun A., Vicens V., Hollander E. Oxytocin can hinder trust and cooperation in borderline personality disorder. Social Cognitive and Affective Neuroscience 2011, 6:556-563.
6. Bartz J.A., Zaki J., Bolger N., Ochsner K.N. Social effects of oxytocin in humans: context and person matter. Trends in Cognitive Sciences 2011, 15:301-309.
7. Bartz J.A., Zaki J., Ochsner K.N., Bolger N., Kolevzon A., Ludwig N., Lydon J.E. Effects of oxytocin on recollections of maternal care and closeness. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:21371-21375.
8. Bertsch K., Gamer M., Schmidt B., Schmidinger I., Walther S., Kästel T., Schnell K., Büchel C., Domes G., Herpertz S.C. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. American Journal of Psychiatry 2013, 170:1169-1177.
9. Blundell J., Blaiss C., Lagace D.C., Eisch A.J., Powell C.M. Block of glucocorticoid synthesis during re-activation inhibits extinction of an established fear memory. Neurobiology of Learning and Memory 2011, 95:453-460.
10. Bohus B., Urban I., van Wimersma Greidanus T.B., de Wied D. Opposite effects of oxytocin and vasopressin on avoidance behaviour and hippocampal theta rhythm in the rat. Neuropharmacology 1978, 17:239-247.
11. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nature Neuroscience 2002, 5:514-516.
12. Bradley R., Ph D., Greene J., Russ E., Dutra L., Westen D., Al E.T. Reviews and overviews a multidimensional meta-analysis of psychotherapy for PTSD. American Journal of Psychiatry 2005, 162:214-227.
13. Cardoso C., Ellenbogen M., Orlando M.A., Bacon S.L., Joober R. Intranasal oxytocin attenuates the cortisol response to physical stress: a dose-response study. Psychoneuroendocrinology 2013, 38:399-407.
14. Chen Y., Fu K., Feng C., Tang L., Zhang J., Huan Y., Cui J., Mu Y., Qi S., Xiong L., Ma C., Wang H., Tan Q., Yin H. Different regional gray matter loss in recent onset PTSD and non PTSD after a single prolonged trauma exposure. PLoS ONE 2012, 7:e48298.
15. Chini B., Leonzino M., Braida D., Sala M. Learning about oxytocin: pharmacologic and behavioral issues. Biological Psychiatry 2013, 1-7.
16. Cloitre M. Effective psychotherapies for posttraumatic stress disorder: a review and critique. CNS Spectrums 2009, 14:32-43.
17. Cohen H., Kaplan Z., Kozlovsky N., Gidron Y., Matar M., Zohar J. Hippocampal microinfusion of oxytocin attenuates the behavioural response to stress by means of dynamic interplay with the glucocorticoid-catecholamine responses. Journal of Neuroendocrinology 2010, 22:889-904.
18. De Kleine R.A., Hendriks G.-J., Kusters W.J.C., Broekman T.G., van Minnen A. A randomized placebo-controlled trial of d-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biological Psychiatry 2012, 71:962-968.
19. De Oliveira D.C.G., Zuardi A.W., Graeff F.G., Queiroz R.H.C., Crippa J.S. Anxiolytic-like effect of oxytocin in the simulated public speaking test. Journal of Psychopharmacology 2012, 26:497-504.
20. De Vries G., Olff M. The lifetime prevalence of traumatic events and posttraumatic stress disorder in the Netherlands. Journal of Traumatic Stress 2009, 22:259-267.
21. De Vries G.J. Sex differences in vasopressin and oxytocin innervation of the brain. Progress in Brain Research 2008, 170:17-27.
22. Delgado M.R., Nearing K.I., Ledoux J.E., Phelps E. Neural circuitry underlying the regulation of conditioned fear and its relation to extinction. Neuron 2008, 59:829-838.
23. Diekhof E.K., Geier K., Falkai P., Gruber O. Fear is only as deep as the mind allows: a coordinate-based meta-analysis of neuroimaging studies on the regulation of negative affect. NeuroImage 2011, 58:275-285.
24. Domes G., Heinrichs M., Gläscher J., Büchel C., Braus D.F., Herpertz S.C. Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biological Psychiatry 2007, 62:1187-1190.
25. Domes G., Lischke A., Berger C., Grossmann A., Hauenstein K., Heinrichs M., Herpertz S.C. Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 2010, 35:83-93.
26. Dunlop B.W., Mansson E., Gerardi M. Pharmacological innovations for posttraumatic stress disorder and medication-enhanced psychotherapy. Current Pharmaceutical Design 2012, 18:5645-5658.
27. Fani N., King T.Z., Jovanovic T., Glover E.M., Bradley B., Choi K., Ely T., Gutman D., Ressler K.J. White matter integrity in highly traumatized adults with and without post-traumatic stress disorder. Neuropsychopharmacology 2012, 37:2740-2746.
28. Foa E.B., Keane T.M., Friedman M.J., Cohen J.A. Effective Treatments for PTSD: Practice Guidelines from the International Society of Traumatic Stress Studies 2009, Guilford Press, New York. 2nd ed.
29. Gilbertson M.W., Shenton M.E., Ciszewski A., Kasai K., Lasko N.B., Orr S.P., Pitman R.K. Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nature Neuroscience 2002, 5:1242-1247.
30. Gossen A., Hahn A., Westphal L., Prinz S., Schultz R.T., Gründer G., Spreckelmeyer K.N. Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men. Neuropeptides 2012, 46:211-215.
31. Grillon C., Krimsky M., Charney D.R., Vytal K., Ernst M., Cornwell B. Oxytocin increases anxiety to unpredictable threat. Molecular Psychiatry 2012, 1-2.
32. Guastella A.J., Einfeld S.L., Gray K.M., Rinehart N.J., Tonge B.J., Lambert T.J., Hickie I.B. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biological Psychiatry 2010, 67:692-694.
33. Guastella A.J., Hickie I.B., McGuinness M.M., Otis M., Woods E., Disinger H.M., Chan H.-K., Chen T.F., Banati R.B. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 2013, 38:612-625.
34. Guastella A.J., Howard A.L., Dadds M.R., Mitchell P., Carson D.S. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009, 34:917-923.
35. Ham B.-J., Chey J., Yoon S.J., Sung Y., Jeong D.-U., Ju Kim S., Sim M.E., Choi N., Choi I.-G., Renshaw P.F., Lyoo I.K. Decreased N-acetyl-aspartate levels in anterior cingulate and hippocampus in subjects with post-traumatic stress disorder: a proton magnetic resonance spectroscopy study. European Journal of Neuroscience 2007, 25:324-329.
36. Hayes J.P., Hayes S.M., Mikedis A.M. Quantitative meta-analysis of neural activity in posttraumatic stress disorder. Biology of Mood & Anxiety Disorders 2012, 2:9.
37. Heinrichs M., Baumgartner T., Kirschbaum C., Ehlert U. Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biological Psychiatry 2003, 54:1389-1398.
38. Huber D., Veinante P., Stoop R. Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 2005, 308:245-248.
39. Jovanovic T., Ely T., Fani N., Glover E.M., Gutman D., Tone E.B., Norrholm S.D., Bradley B., Ressler K.J. Reduced neural activation during an inhibition task is associated with impaired fear inhibition in a traumatized civilian sample. Cortex 2012, 49:1884-1891.
40. Jovanovic T., Norrholm S.D., Blanding N.Q., Davis M., Duncan E., Bradley B., Ressler K.J. Impaired fear inhibition is a biomarker of PTSD but not depression. Depression and Anxiety 2010, 27:244-251.
41. Jovanovic T., Norrholm S.D., Fennell J.E., Keyes M., Fiallos A.M., Myers K.M., Davis M., Duncan E.J. Posttraumatic stress disorder may be associated with impaired fear inhibition: relation to symptom severity. Psychiatry Research 2009, 167:151-160.
42. Jovanovic T., Ressler K.J. How the neurocircuitry and genetics of fear inhibition may inform our understanding of PTSD. American Journal of Psychiatry 2010, 167:648-662.
43. Kalisch R., Korenfeld E., Stephan K.E., Weiskopf N., Seymour B., Dolan R.J. Context-dependent human extinction memory is mediated by a ventromedial prefrontal and hippocampal network. Journal of Neuroscience 2006, 26:9503-9511.
44. Karl A., Schaefer M., Malta L.S., Dörfel D., Rohleder N., Werner A. A meta-analysis of structural brain abnormalities in PTSD. Neuroscience and Biobehavioral Reviews 2006, 30:1004-1031.
45. Kim M.J., Gee D.G., Loucks R., Davis F.C., Whalen P.J. Anxiety dissociates dorsal and ventral medial prefrontal cortex functional connectivity with the amygdala at rest. Cerebral Cortex 2011, 21:1667-1673.
46. Kim M.J., Loucks R., Palmer A.L., Brown A.C., Solomon K.M., Marchante A.N., Whalen P.J. The structural and functional connectivity of the amygdala: from normal emotion to pathological anxiety. Behavioural Brain Research 2011, 223:403-410.
47. Kim M.J., Whalen P.J. The structural integrity of an amygdala-prefrontal pathway predicts trait anxiety. Journal of Neuroscience 2009, 29:11614-11618.
48. Kirsch P., Esslinger C., Chen Q., Mier D., Lis S., Siddhanti S., Gruppe H., Mattay V.S., Gallhofer B., Meyer-Lindenberg A. Oxytocin modulates neural circuitry for social cognition and fear in humans. Journal of Neuroscience 2005, 25:11489-11493.
49. Koenigs M., Huey E.D., Raymont V., Cheon B., Solomon J., Wassermann E.M., Grafman J. Focal brain damage protects against post-traumatic stress disorder in combat veterans. Nature Neuroscience 2008, 11:232-237.
50. Kubzansky L.D., Mendes W.B., Appleton A., Block J., Adler G.K. A heartfelt response: oxytocin effects on response to social stress in men and women. Biological Psychology 2012, 90:1-9.
51. Kühn S., Gallinat J. Gray matter correlates of posttraumatic stress disorder: a quantitative meta-analysis. Biological Psychiatry 2013, 73:70-74.
52. Kuo J.R., Kaloupek D.G., Woodward S.H. Amygdala volume in combat-exposed veterans with and without posttraumatic stress disorder: a cross-sectional study. Archives of General Psychiatry 2012, 69:1080-1086.
53. Labuschagne I., Phan K.L., Wood A., Angstadt M., Chua P., Heinrichs M., Stout J.C., Nathan P.J. Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 2010, 35:2403-2413.
54. Labuschagne I., Phan K.L., Wood A., Angstadt M., Chua P., Heinrichs M., Stout J.C., Nathan P.J. Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. International Journal of Neuropsychopharmacology 2011, 15:883-896.
55. Lanius R.A., Bluhm R.L., Coupland N.J., Hegadoren K.M., Rowe B., Théberge J., Neufeld R.W.J., Williamson P.C., Brimson M. Default mode network connectivity as a predictor of post-traumatic stress disorder symptom severity in acutely traumatized subjects. Acta Psychiatrica Scandinavica 2010, 121:33-40.
56. Linnman C., Zeffiro T.A., Pitman R.K., Milad M.R. An fMRI study of unconditioned responses in post-traumatic stress disorder. Biology of Mood & Anxiety Disorders 2011, 1:8.
57. Lischke A., Gamer M., Berger C., Grossmann A., Hauenstein K., Heinrichs M., Herpertz S.C., Domes G. Oxytocin increases amygdala reactivity to threatening scenes in females. Psychoneuroendocrinology 2012, 37:1431-1438.
58. Lommen M.J.J., Engelhard I.M., Sijbrandij M., van den Hout M., Hermans D. Pre-trauma individual differences in extinction learning predict posttraumatic stress. Behaviour Research and Therapy 2013, 51:63-67.
59. Lukas M., Toth I., Reber S.O., Slattery D., Veenema A.H., Neumann I.D. The neuropeptide oxytocin facilitates pro-social behavior and prevents social avoidance in rats and mice. Neuropsychopharmacology 2011, 36:2159-2168.
60. MacDonald E., Dadds M.R., Brennan J.L., Williams K., Levy F., Cauchi A.J. A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research. Psychoneuroendocrinology 2011, 36:1114-1126.
61. Macdonald K., Feifel D. Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders. Frontiers in Neuroscience 2013, 7:35.
62. Macdonald K., Macdonald T.M., Brüne M., Lamb K., Wilson M.P., Golshan S., Feifel D. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology 2013, 38:2831-2843.
63. McRae K., Hughes B., Chopra S., Gabrieli J.D.E., Gross J.J., Ochsner K.N. The neural bases of distraction and reappraisal. Journal of Cognitive Neuroscience 2010, 22:248-262.
64. Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends in Cognitive Sciences 2011, 15:483-506.
65. Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M. Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine. Nature reviews. Neuroscience 2011, 12:524-538.
66. Milad M.R., Orr S.P., Lasko N.B., Chang Y., Rauch S.L., Pitman R.K. Presence and acquired origin of reduced recall for fear extinction in PTSD: results of a twin study. Journal of Psychiatric Research 2008, 42:515-520.
67. Milad M.R., Quinn B.T., Pitman R.K., Orr S.P., Fischl B., Rauch S.L. Thickness of ventromedial prefrontal cortex in humans is correlated with extinction memory. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:10706-10711.
68. Milad M.R., Quirk G.J., Pitman R.K., Orr S.P., Fischl B., Rauch S.L. A role for the human dorsal anterior cingulate cortex in fear expression. Biological Psychiatry 2007, 62:1191-1194.
69. Milad M.R., Wright C.I., Orr S.P., Pitman R.K., Quirk G.J., Rauch S.L. Recall of fear extinction in humans activates the ventromedial prefrontal cortex and hippocampus in concert. Biological Psychiatry 2007, 62:446-454.
70. Miller G. The promise and perils of oxytocin. Science 2013, 339:267-269.
71. Mithoefer M.C., Wagner M.T., Mithoefer A.T., Jerome L., Doblin R. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. Journal of Psychopharmacology 2011, 25:439-452.
72. Modabbernia A., Rezaei F., Salehi B., Jafarinia M., Ashrafi M., Tabrizi M., Hosseini S.M.R., Tajdini M., Ghaleiha A., Akhondzadeh S. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia: an 8-week, randomized, double-blind, placebo-controlled study. CNS Drugs 2013, 27:57-65.
73. Morey R.A., Gold A.L., LaBar K.S., Beall S.K., Brown V.M., Haswell C.C., Nasser J.D., Wagner H.R., McCarthy G. Amygdala volume changes in posttraumatic stress disorder in a large case-controlled veterans group. Archives of General Psychiatry 2012, 69:1169-1178.
74. Neumann I.D., Maloumby R., Beiderbeck D.I., Lukas M., Landgraf R. Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice. Psychoneuroendocrinology 2013, 38:1985-1993.
75. Ochsner K.N., Bunge S.A., Gross J.J., Gabrieli J.D.E. Rethinking feelings: an FMRI study of the cognitive regulation of emotion. Journal of Cognitive Neuroscience 2002, 14:1215-1229.
76. Olff M., Frijling J.L., Kubzansky L.D., Bradley B., Ellenbogen M., Cardoso C., Bartz J., Yee J.R., van Zuiden M. The role of oxytocin in social bonding, stress regulation and mental health: an update on the moderating effects of context and interindividual differences. Psychoneuroendocrinology 2013.
77. Olff M., Langeland W., Draijer N., Gersons B.P.R. Gender differences in posttraumatic stress disorder. Psychological Bulletin 2007, 133:183-204.
78. Olff M., Langeland W., Witteveen A., Denys D. A psychobiological rationale for oxytocin in the treatment of posttraumatic stress disorder. CNS Spectrums 2010, 15:522-530.
79. Patel R., Spreng R.N., Shin L.M., Girard T.A. Neurocircuitry models of posttraumatic stress disorder and beyond: a meta-analysis of functional neuroimaging studies. Neuroscience and Biobehavioral Reviews 2012, 36:2130-2142.
80. Pedersen C.A., Gibson C.M., Rau S.W., Salimi K., Smedley K.L., Casey R.L., Leserman J., Jarskog L.F., Penn D.L. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophrenia research 2011, 132:50-53.
81. Pejic T., Hermann A., Vaitl D., Stark R. Social anxiety modulates amygdala activation during social conditioning. Social Cognitive and Affective Neuroscience 2013, 8:267-276.
82. Petersson M., Hulting A.L., Uvnäs-Moberg K. Oxytocin causes a sustained decrease in plasma levels of corticosterone in rats. Neuroscience Letters 1999, 264:41-44.
83. Petrovic P., Kalisch R., Singer T., Dolan R.J. Oxytocin attenuates affective evaluations of conditioned faces and amygdala activity. Journal of Neuroscience 2008, 28:6607-6615.
84. Pezawas L., Meyer-Lindenberg A., Drabant E.M., Verchinski B., Munoz K.E., Kolachana B.S., Egan M.F., Mattay V.S., Hariri A.R., Weinberger D.R. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nature Neuroscience 2005, 8:828-834.
85. Phelps E., Delgado M.R., Nearing K.I., LeDoux J.E. Extinction learning in humans: role of the amygdala and vmPFC. Neuron 2004, 43:897-905.
86. Pitman R.K., Orr S.P., Lasko N.B. Effects of intranasal vasopressin and oxytocin on physiologic responding during personal combat imagery in Vietnam veterans with posttraumatic stress disorder. Psychiatry Research 1993, 48:107-117.
87. Pohlack S.T., Nees F., Liebscher C., Cacciaglia R., Diener S.J., Ridder S., Woermann F.G., Flor H. Hippocampal but not amygdalar volume affects contextual fear conditioning in humans. Human Brain Mapping 2012, 33:478-488.
88. Quidé Y., Witteveen A.B., El-Hage W., Veltman D.J., Olff M. Differences between effects of psychological versus pharmacological treatments on functional and morphological brain alterations in anxiety disorders and major depressive disorder: a systematic review. Neuroscience and Biobehavioral Reviews 2012, 36:626-644.
89. Quirin M., Kuhl J., Düsing R. Oxytocin buffers cortisol responses to stress in individuals with impaired emotion regulation abilities. Psychoneuroendocrinology 2011, 36:898-904.
90. Riem M.M.E., Bakermans-Kranenburg M.J., Pieper S., Tops M., Boksem M.S., Vermeiren R.R.J.M., van Ijzendoorn M.H., Rombouts S.R.B. Oxytocin modulates amygdala, insula, and inferior frontal gyrus responses to infant crying: a randomized controlled trial. Biological Psychiatry 2011, 70:291-297.
91. Riem M.M.E., van IJzendoorn M.H., Tops M., Boksem M.S., Rombouts S.R.B., Bakermans-Kranenburg M.J. No laughing matter: intranasal oxytocin administration changes functional brain connectivity during exposure to infant laughter. Neuropsychopharmacology 2012, 37:1257-1266.
92. Rilling J.K., DeMarco A.C., Hackett P.D., Thompson R., Ditzen B., Patel R., Pagnoni G. Effects of intranasal oxytocin and vasopressin on cooperative behavior and associated brain activity in men. Psychoneuroendocrinology 2012, 37:447-461.
93. Rodrigues S.M., LeDoux J.E., Sapolsky R.M. The influence of stress hormones on fear circuitry. Annual Review of Neuroscience 2009, 32:289-313.
94. Rothbaum B.O., Davis M. Applying learning principles to the treatment of post-trauma reactions. Annals of the New York Academy of Sciences 2003, 1008:112-121.
95. Rupp H., James T.W., Ketterson E.D., Sengelaub D.R., Ditzen B., Heiman J.R. Amygdala response to negative images in postpartum vs. nulliparous women and intranasal oxytocin. Social Cognitive and Affective Neuroscience 2012, 1-7.
96. Sartory G., Cwik J., Knuppertz H., Schürholt B., Lebens M., Seitz R.J., Schulze R. In search of the trauma memory: a meta-analysis of functional neuroimaging studies of symptom provocation in posttraumatic stress disorder (PTSD). PLoS ONE 2013, 8:e58150.
97. Seeley W.W., Menon V., Schatzberg A.F., Keller J., Glover G.H., Kenna H., Reiss A.L., Greicius M.D. Dissociable intrinsic connectivity networks for salience processing and executive control. Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2007, 27:2349-2356.
98. Shin L.M., Bush G., Milad M.R., Lasko N.B., Brohawn K.H., Hughes K.C., Macklin M.L., Gold A.L., Karpf R.D., Orr S.P., Rauch S.L., Pitman R.K. Exaggerated activation of dorsal anterior cingulate cortex during cognitive interference: a monozygotic twin study of posttraumatic stress disorder. American Journal of Psychiatry 2011, 168:979-985.
99. Shu X.-J., Xue L., Liu W., Chen F.-Y., Zhu C., Sun X.-H., Wang X.-P., Liu Z.-C., Zhao H. More vulnerability of left than right hippocampal damage in right-handed patients with post-traumatic stress disorder. Psychiatry Research 2013, 212:237-244.
100. Simmons A., Strigo I., Matthews S.C., Paulus M.P., Stein M.B. Anticipation of aversive visual stimuli is associated with increased insula activation in anxiety-prone subjects. Biological Psychiatry 2006, 60:402-409.
101. Sripada C.S., Phan K.L., Labuschagne I., Welsh R., Nathan P.J., Wood A.G. Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. International Journal of Neuropsychopharmacology 2013, 16:255-260.
102. Sripada R.K., King A.P., Welsh R.C., Garfinkel S.N., Wang X., Sripada C.S., Liberzon I. Neural dysregulation in posttraumatic stress disorder: evidence for disrupted equilibrium between salience and default mode brain networks. Psychosomatic Medicine 2012, 74:904-911.
103. Striepens N., Scheele D., Kendrick K.M., Becker B., Schäfer L., Schwalba K., Reul J., Maier W., Hurlemann R. Oxytocin facilitates protective responses to aversive social stimuli in males. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:18144-18149.
104. Taylor S.E., Klein L.C., Lewis B.P., Gruenewald T.L., Gurung R.A.R., Updegraff J.A. Biobehavioral responses to stress in females: tend-and-befriend, not fight-or-flight. Psychological Review 2000, 107:411-429.
105. Thomaes K., Dorrepaal E., Draijer N., de Ruiter M.B., Elzinga B.M., Sjoerds Z., van Balkom A.J., Smit J.H., Veltman D.J. Increased anterior cingulate cortex and hippocampus activation in Complex PTSD during encoding of negative words. Social Cognitive and Affective Neuroscience 2013, 8:190-200.
106. Toth I., Neumann I.D., Slattery D. Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner. Psychopharmacology 2012, 223:149-158.
107. van Ijzendoorn M.H., Bhandari R., van der Veen R., Grewen K.M., Bakermans-Kranenburg M.J. Elevated salivary levels of oxytocin persist more than 7h after intranasal administration. Frontiers in Neuroscience 2012, 6:174.
108. Viviani D., Charlet A., van den Burg E., Robinet C., Hurni N., Abatis M., Magara F., Stoop R. Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. Science 2011, 333:104-107.
109. Wang Z., Neylan T.C., Mueller S.G., Lenoci M., Truran D., Marmar C.R., Weiner M.W., Schuff N. Magnetic resonance imaging of hippocampal subfields in posttraumatic stress disorder. Archives of General Psychiatry 2010, 67:296-303.
110. Woon F., Hedges D. Amygdala volume in adults with posttraumatic stress disorder: a meta-analysis. Journal of Neuropsychiatry and Clinical Neurosciences 2009, 21:5-12.
111. Yatzkar U., Klein E. P.3026 Intranasal oxytocin in patients with post traumatic stress disorder: a single dose, pilot double blind crossover study. European Neuropsychopharmacology 2010, 20:S84.
112. Zhou Y., Wang Z., Qin L., Wan J., Sun Y., Su S., Ding W., Xu J. Early altered resting-state functional connectivity predicts the severity of post-traumatic stress disorder symptoms in acutely traumatized subjects. PLoS ONE 2012, 7:e46833.